Tarsus Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Tarsus Pharmaceuticals, Inc. reports significant revenue growth from its flagship product XDEMVY, while continuing to advance its pipeline for ocular rosacea and Lyme disease prophylaxis.
NASDAQ
Tarsus Pharmaceuticals' 10-K filing highlights successful XDEMVY launch with $180.1 million in sales, expansion plans in Europe and Japan, and a potential partnership for its Lyme disease program.
NASDAQ
Tarsus Pharmaceuticals' 2023 annual report highlights the successful launch of XDEMVY for Demodex blepharitis and advancements in its pipeline, including positive clinical trial results for MGD, rosacea, and Lyme disease.